In one paragraphArticle in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
J Ahuixotl Gutiérrez-AcevesPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Felipe Alexis Avalos-SalgadoPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-5328-4519 Jorge Ivan Gamez-NavaPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-0001-3787 Laura Gonzalez-LopezPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-6517-6344 Sergio Antonio González-VázquezHospital General Regional 110, Instituto Mexicano del Seguro Social, Guadalajara 44716, Mexico.
Reynaldo Arellano-CervantesPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Mario Alberto Mireles-RamírezHospital de Especialidades CMNO, Division de Investigación en Salud. Av. Belisario Domínguez 999, Independencia Oriente, Guadalajara 44340, Mexico.ORCID 0000-0002-8321-7883 Jazmin Marquez-PedrozaNeurosciences Division, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara 44340, Mexico.ORCID 0000-0003-2859-726X Melissa Ramirez-VillafañaInstituto de Terapéutica Experimental y Clínica, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-5975-8532 Eli Efrain Gomez-RamirezInstituto de Terapéutica Experimental y Clínica, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Fabiola Gonzalez-PonceResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-1932-6003 Ana Miriam Saldaña-CruzResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-2272-9612 Norma Alejandra Rodriguez-JimenezResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-7643-6298 Ernesto German Cardona-MuñozResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Sylvia Totsuka-SuttoResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Juan Manuel Ponce-GuarnerosResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-5035-3347 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Urinary tract infections (UTIs) constitute one of the main complications in kidney recipients, increasing both morbidity and mortality. Due to the resurgence of antimicrobial resistance, new prophylactic approaches are being investigated. Nitrofurantoin is an antibiotic from the nitrofuran group that is effective against several Gram-negative and Gram-positive organisms; hence, there has been a resurgence in its prescription for treating MDR pathogens.
Indexed as
antimicrobial resistancecohort studykidney transplantnitrofurantoinprophylactic treatmenturinary tract infection
Identifiers
PMID39274431
PMCPMC11396127
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390